1. Harnessing the Power of
CellsTM
New Assays for
Musculoskeletal Disorders Drug
Discovery
Executive Overview
1

2. Solutions for Musculoskeletal Disease Research
Potent Umbilical Cord Blood Derived Human Mesenchymal Stem Cells
 Alternative to induced pluripotent and embryonic stem cells
 Phenotypically and morphologically stable through 50 population doublings
 HLA-DR-, CD14-, CD19-, CD31-, CD34-, CD41a-, CD235a-, ALP-, CD271-
CD45-, D7FIB++++, CD44++++, CD54++++, CD73++++, CD90++++,
CD105++++, CD140b++++, CD166++++, CD146++++
 Capacity to produce cell numbers required for high throughput & content
screening
Differentiated Cells: Osteoblasts,
Chondrocytes and Fibroblasts
Potent Media
 Low serum and clinical grade, serum
free expansion media
 Osteogenesis, chondrogenesis &
adipogenesis media
 Stem cell basal media
MSCGroTM Media vs Lonza
1 6-1-2013 2

3. Potent Cells and Media-Better Results=Lower Costs
2 4/30/2013 3
Our Media Keeps your Cells Going and Going “We tested the
effects of MSCTMGro defined medium using several different
lots of human adult primary stem cells and found that
MSCGro supports a more robust proliferation rate than
normal undefined media. This provided shorter doubling
times and increased cellular yield, and maintained the cells in
an undifferentiated state. We also found that MSCGro
medium is stable under normal laboratory conditions for an
extended time period compared to other defined media.” Ben
Buehrer, VP and CSO, Zen-Bio
Images: (A) Human cord-blood MSCs were expanded in
low-serum MSC-GroTM to confluence as shown here. (B)
were differentiated in osteogenic MSC-GroTM. Early stage
osteoblasts are shown here; the arrow shows early
formation of mineralized matrix. (C)&(D) Mature
osteoblasts stained positive for Alizarin red. Phase contrast
image at 200 x, scale bar is 50 mmeters.

4. Potent Cells and Media-Better Results=Lower Costs
2 4/30/2013 4
Human Fibroblasts
Images: Pancreatic stellate cells are positive for GFAP and a -SMA.
Immunofluorescence analysis of representative primary PSC lines grown on
chamber slides. Cells were stained with 40, 6-diamidino-2-phenylindole (DAPI;
blue) and antibodies (green) for vimentin, GFAP, and alpha-SMA. The human
PANC-1 cell and HPF line were negative controls for alpha-SMA staining. Slides
were visualized at 40 magnification. Published OnlineFirst March 20, 2013; doi:
10.1158/0008-5472.CAN-12-4601. Cancer Res May 15, 2013 73; 3007.
Figure: Continuous expansion of human fibroblasts.
Cells expanded through 16 passages. Fibroblast
were plated at 5,000 cells/cm2 in Greiner Bio-one
T25 flasks maintained in VitroPlus III, low serum
media in a reduced oxygen environment (5% O2, 5%
CO2, 90% N2) at 37OF in a humidified chamber. The
pancreatic fibroblasts were detached using by
incubation in AccutaseTM they were approximately at
80-90% confluency and counted using a Beckman-
Coulter Z2.

5. Potent Cells and Media-Summary
3 4/30/2013 5
Cells are differentiated from human MSCs-
Competitive to IPSCs since there is no
reprogramming nor epigenetic issues intrinsic to
IPSCs
Cost-effective due to manufacturing scalability
Direct purchase without licensing requirement
Highly experienced team with extensive technical and
biopharma partnership experience.
Cell therapy application as well as discovery.

6. Capabilities meet HCS/HTS Requirements
 Cost-effective materials to meet target per well costs
 Human cells reduce false positives vs. animal tissues
 Cells express proteins of interest. Verification assays provided
based on specific requirements.
 Readily scalable: Identical phenotype/genotype from pilot to
screening mode.
 Co-culture capability for custom assays.
 E.g., chondrocyte/osteoblasts
4 4/30/2013 6

7. Evaluation Process
 Confidential discussion of Specific Disorder, Therapeutic Target(s) and cell
based assay requirements.
 Design pilot assay with deliverables and milestones
 Review milestone data vs requirements
 Revise assay as needed
 Determine final assay configuration.
 Determine scale up requirements
 Cost targets
 Material and deliverables
 Evaluate progress vs plans and adjust accordingly
 Position capabilities for future projects
5 4/30/2013 7

8. Contacts
Technical and Consulting:
Dr. Jim Musick
President
Vitro Biopharma
jim@vitrobiopharma.com
(303) 999-2130
4621 Technology Drive
Golden, CO 80403
Sales/Proposal Process
Pete Shuster
CEO
Neuromics
pshuster@neuromics.com
612-801-1007
5325 West 74ths Street
Edina, MN 55439
Draft 1 04-2013-3 8